A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II)

BACKGROUND: On the basis of international clinical trials, capecitabine plus cisplatin (XP) as a first-line treatment of advanced gastric cancer is considered a global standard regimen. However, the usefulness of XP as compared with S-1 plus cisplatin (SP), which is considered standard therapy in Ja...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuburaya, Akira, Morita, Satoshi, Kodera, Yasuhiro, Kobayashi, Michiya, Shitara, Kohei, Yamaguchi, Kensei, Yoshikawa, Takaki, Yoshida, Kazuhiro, Yoshino, Shigefumi, Sakamoto, Jun-ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488329/
https://www.ncbi.nlm.nih.gov/pubmed/22824079
http://dx.doi.org/10.1186/1471-2407-12-307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488329/
https://www.ncbi.nlm.nih.gov/pubmed/22824079
http://dx.doi.org/10.1186/1471-2407-12-307

Ejemplares similares